Loading...
Market
What sales milestone will KarXT (Cobenfy) achieve within the first year of launch?
2
Resolution / Starting Odds
Less than $250 million • 25%
$250 million to $499 million • 25%
$500 million to $749 million • 25%
$750 million or more • 25%
Bristol Myers Squibb's official financial reports or press releases
Story
FDA Approves Bristol Myers Squibb's New Schizophrenia Drug KarXT, Brand Name Cobenfy
Sep 26, 2024, 10:44 PM
The U.S. Food and Drug Administration (FDA) has approved KarXT, a new schizophrenia drug developed by Bristol Myers Squibb, on Thursday. This marks the first new type of treatment for schizophrenia in decades and offers a significant advancement in the management of the mental disorder. KarXT, also known by its brand name Cobenfy, is notable for its effectiveness and milder side effects compared to existing treatments. The drug, approved for oral use, is a major milestone for patients and the pharmaceutical industry, as it brings renewed focus to neuropsychiatric treatments.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
< 50,000 • 25%
50,000 - 100,000 • 25%
100,000 - 200,000 • 25%
> 200,000 • 25%
Yes • 50%
No • 50%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative impact • 25%